植入式迷走神經刺激系統(Vagus Nerve Stimulation (VNS Therapy™) System)用於重度憂鬱症:根據歐洲研究使用一年後有效者53%,治癒率33%;副作用包括聲音改變(63%)及咳嗽(23%)
Vagus nerve stimulation for depression: efficacy and safety in a European study.
Psychol Med. 2008; 38(5):651-61 (ISSN: 0033-2917)
Schlaepfer TE; Frick C; Zobel A; Maier W; Heuser I; Bajbouj M; O'Keane V; Corcoran C; Adolfsson R; Trimble M; Rau H; Hoff HJ; Padberg F; Müller-Siecheneder F; Audenaert K; Van den Abbeele D; Matthews K; Christmas D; Stanga Z; Hasdemir M
Departments of Psychiatry, University Hospital, Bern, Switzerland. email@example.com
BACKGROUND: Vagus nerve stimulation (VNS) therapy is associated with a decrease in seizure frequency in partial-onset seizure patients. Initial trials suggest that it may be an effective treatment, with few side-effects, for intractable depression. METHOD: An open, uncontrolled European multi-centre study (D03) of VNS therapy was conducted, in addition to stable pharmacotherapy, in 74 patients with treatment-resistant depression (TRD). Treatment remained unchanged for the first 3 months; in the subsequent 9 months, medications and VNS dosing parameters were altered as indicated clinically. RESULTS: The baseline 28-item Hamilton Depression Rating Scale (HAMD-28) score averaged 34. After 3 months of VNS, response rates (> or = 50% reduction in baseline scores) reached 37% and remission rates (HAMD-28 score <10) 17%. Response rates increased to 53% after 1 year of VNS, and remission rates reached 33%. Response was defined as sustained if no relapse occurred during the first year of VNS after response onset; 44% of patients met these criteria. Median time to response was 9 months. Most frequent side-effects were voice alteration (63% at 3 months of stimulation) and coughing (23%). CONCLUSIONS: VNS therapy was effective in reducing severity of depression; efficacy increased over time. Efficacy ratings were in the same range as those previously reported from a USA study using a similar protocol; at 12 months, reduction of symptom severity was significantly higher in the European sample. This might be explained by a small but significant difference in the baseline HAMD-28 score and the lower number of treatments in the current episode in the European study.